6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors
Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
1. The compound cis-3-[8-amino-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-3-yl]-1-methyl-cyclobutanol or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
3. A pharmaceutical composition comprising the compound of claim 1 in an amount of about 100 mg, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
4. A method of treating lung cancer mediated by IGF-1R comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
5. The method of claim 4 , which comprises orally administering to the patient a dosage form containing about 100 mg of the compound or a pharmaceutically acceptable salt thereof.
6. A method of treating breast cancer mediated by IGF-1R comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
7. The method of claim 6 , which comprises orally administering to the patient a dosage form containing about 100 mg of the compound or a pharmaceutically acceptable salt thereof.
8. A method of treating colon cancer mediated by IGF-1R comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
9. The method of claim 8 , which comprises orally administering to the patient a dosage form containing about 100 mg of the compound or a pharmaceutically acceptable salt thereof.